ENDPOINTS

Curie.Bio has a new $340M fund; Layoffs at Benchling, I-Mab

3 months ago

News Briefing

Key GOP senator is ‘struggling’ with Kennedy nomination over vaccine answers

3 months ago

People

Pharma

Trump blog: Federal agencies must give jobs back to fired probationary workers, judge rules

3 months ago

Pharma

FDA+

Boehringer merges cancer vaccine and oncolytic virus teams; Dantari sells off assets

4 months ago

News Briefing

FDA delays decision on Stealth’s Barth syndrome drug; TargetRx raises $50M

4 months ago

News Briefing

Shanghai Bao, Sichuan Biokin file IPOs in Hong Kong; Disc's $200M offering

4 months ago

News Briefing

FDA puts Atara’s INDs on hold after rejection; Ascletis' safety data for obesity pill

4 months ago

News Briefing

WuXi AppTec sells medical device testing unit; Layoffs at Notch Therapeutics

4 months ago

News Briefing

Boehringer's schizophrenia asset fails Phase 3; GSK buys organoid biotech

4 months ago

News Briefing

Hinge Bio's $30M raise; Keros reports additional issues in Phase 2 PAH trial

4 months ago

News Briefing

#JPM25 live blog day 3: PhRMA chief on reforming the IRA; Gilead weighs in on China dealmaking

4 months ago

Pharma

Regeneron, Illumina invest in Truveta; Inhibrx Bio’s $150M loan

4 months ago

News Briefing

#JPM25 live blog day 2: Nvidia makes it fun; The year's 10th megaround

4 months ago

Pharma

Immunovant’s $450M private placement; Biomea becomes an obesity biotech

4 months ago

News Briefing

#JPM25 live blog day 1: How will Trump 2.0 impact the biopharma industry? Scott Gottlieb, Bob Nelsen share ...

4 months ago

Deals

Pharma

Stemson Therapeutics shutters; Insilico teams up again with Menarini

4 months ago

News Briefing

Numab extends its Series C; AnaCardio raises $19M for its heart failure drug

4 months ago

News Briefing

Sana’s stock soars on new cell therapy data; UniQure’s $75M offering

4 months ago

News Briefing

Novo Nordisk partners with Variant Bio; Aviceda raises $207M in Series C

4 months ago

News Briefing

I-Mab stops work on CD73; Citius to pursue ‘strategic’ options

4 months ago

News Briefing

Every FDA drug approval from 2024: Fewer nods, but long-awaited treatments cross the finish line

4 months ago

Pharma

FDA+

Hutchmed’s divestiture; Xgene reports Phase 2b win for non-opioid pain drug

4 months ago

News Briefing

Novartis ends Phase 1 radiopharma trial; Solve Therapeutics pursues $75M round

4 months ago

News Briefing

PDUFAs for Tonix and Nuvation; Sanofi vaccine partnership; RAPT allergy deal

5 months ago

Deals

News Briefing

about the author

author articles

Curie.Bio has a new $340M fund; Layoffs at Benchling, I-Mab

Key GOP senator is ‘struggling’ with Kennedy nomination over vaccine answers

Trump blog: Federal agencies must give jobs back to fired probationary workers, judge rules

Boehringer merges cancer vaccine and oncolytic virus teams; Dantari sells off assets

FDA delays decision on Stealth’s Barth syndrome drug; TargetRx raises $50M

Shanghai Bao, Sichuan Biokin file IPOs in Hong Kong; Disc's $200M offering

FDA puts Atara’s INDs on hold after rejection; Ascletis' safety data for obesity pill

WuXi AppTec sells medical device testing unit; Layoffs at Notch Therapeutics

Boehringer's schizophrenia asset fails Phase 3; GSK buys organoid biotech

Hinge Bio's $30M raise; Keros reports additional issues in Phase 2 PAH trial

#JPM25 live blog day 3: PhRMA chief on reforming the IRA; Gilead weighs in on China dealmaking

Regeneron, Illumina invest in Truveta; Inhibrx Bio’s $150M loan

#JPM25 live blog day 2: Nvidia makes it fun; The year's 10th megaround

Immunovant’s $450M private placement; Biomea becomes an obesity biotech

#JPM25 live blog day 1: How will Trump 2.0 impact the biopharma industry? Scott Gottlieb, Bob Nelsen share ...

Stemson Therapeutics shutters; Insilico teams up again with Menarini

Numab extends its Series C; AnaCardio raises $19M for its heart failure drug

Sana’s stock soars on new cell therapy data; UniQure’s $75M offering

Novo Nordisk partners with Variant Bio; Aviceda raises $207M in Series C

I-Mab stops work on CD73; Citius to pursue ‘strategic’ options

Every FDA drug approval from 2024: Fewer nods, but long-awaited treatments cross the finish line

Hutchmed’s divestiture; Xgene reports Phase 2b win for non-opioid pain drug

Novartis ends Phase 1 radiopharma trial; Solve Therapeutics pursues $75M round

PDUFAs for Tonix and Nuvation; Sanofi vaccine partnership; RAPT allergy deal